Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population Pharmacokinetic Modeling and Simulation to Support the Regulatory Submission of the Two-Injection Start Regimen with Aripiprazole Once-Monthly Long-Acting Injectable Intramuscular Administration in Japanese Patients with Schizophrenia or Bipolar I Disorder.

Journal of clinical pharmacology·2026
Same author

Association Between Health Literacy and One-Year Incidence of Pre-Frailty Among Older Adults Undergoing Frailty Health Checkups.

Geriatrics (Basel, Switzerland)·2026
Same author

Identification of Urinary Exosomal microRNAs Associated With Subclinical Acute T-Cell-Mediated Rejection in Kidney Transplant Recipients.

Clinical and translational science·2026
Same author

Effect of Probiotics on Immunosuppressive Drug Pharmacokinetics: Interaction between Bacillus subtilis and Tacrolimus in Mice.

Biological & pharmaceutical bulletin·2025
Same author

Quantitative Evaluation of Nemolizumab Pharmacokinetics and Efficacy in Prurigo Nodularis: A Population Pharmacokinetics and Model-Based Meta-analysis Approach.

Dermatology and therapy·2025
Same author

Examination of Social Participation in Older Adults Undergoing Frailty Health Checkups Using Deep Learning Models.

Geriatrics (Basel, Switzerland)·2025

Related Experiment Video

Updated: Jun 21, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian

Tomohiro Sasaki1, Hiroko Tabuchi, Shun Higuchi

  • 1Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.

Pharmacogenomics
|August 12, 2009
PubMed
Summary

A new warfarin dosing algorithm using population pharmacokinetic/pharmacodynamic (PK/PD) modeling and Bayesian forecasting accurately predicts maintenance doses for individualized warfarin therapy. This approach enhances treatment precision.

Related Experiment Videos

Last Updated: Jun 21, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Area of Science:

  • Pharmacology
  • Pharmacokinetics
  • Pharmacodynamics

Background:

  • Warfarin dosing requires precise management due to its narrow therapeutic index.
  • Existing dosing algorithms may not fully capture individual patient variability.

Purpose of the Study:

  • To develop and validate a novel warfarin-dosing algorithm.
  • To integrate population pharmacokinetic/pharmacodynamic (PK/PD) modeling with Bayesian forecasting.
  • To facilitate individualized warfarin therapy.

Main Methods:

  • Utilized CYP2C9 and VKORC1 genotypes, S-warfarin levels, and INR.
  • Estimated individual PK (CLs) and PD (EC50) parameters via Bayesian forecasting.
  • Developed a multiple linear regression model for maintenance dose prediction.
  • Validated the model using bootstrap resampling and cross-validation.

Main Results:

  • The algorithm accurately predicted S-warfarin plasma concentrations and INR.
  • A strong correlation (r² = 0.944) was observed between actual and predicted maintenance doses.
  • The developed model demonstrated robust and superior predictive performance compared to other methods.

Conclusions:

  • A novel algorithm integrating PK/PD modeling and Bayesian forecasting enables precise warfarin maintenance dose prediction.
  • This approach supports individualized warfarin therapy, improving treatment outcomes.
  • The algorithm's accuracy was validated through rigorous statistical methods.